Thursday, 19 Jul 2018

You are here

Cardiac Disturbances Increased in Spondyloarthritis

A prospective nationwide study from Sweden analyzed patients with AS (n=6448), PsA (n=16 063),  undifferentiated spondyloarthritis (uSpA; n=5190) and a general population controls (GP; n=2 66 435) between 2001–2009 and found a higher risk of aortic regurgitation and pacemaker use in SpA and higher risk of AV block, especially in men with AS or uSpA.

Atrial fibrillation (AF) wsa most common cardiac abnormality (5.5–7.4 events per 1000 person-years), followed by pacemaker implantation (PM) (1.0–2.0 events per 1000 person-years).

AS patients had significantly  increased hazard rations (HR) for AV block (HR 2.3), AF (1.2), PM (2.1) and aortic regurgitation (1.9). Higher  rates of all of these were seen in uSpA (HRs 2.9, 1.3, 1.9 and 2.0, respectively) and PsA (HRs 1.5, 1.5, 1.6 and 1.8, respectively) compared to controls.

The highest HRs were seen for AV block in male uSpA (HR 4.2) and AS (HR 2.5) compared with GP.

Pacemakers were higher in AS (HR 1.5) and AV blodk was also higher in uSpA (HR 1.5) when compared to PsA patients.

Conduction and valvular dysfunction is more common amongst SpA patients and should be screened for, especially in men.

The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Liver Disease Increased in Psoriasis

An observational case-control study has shown that psoriasis is associated with an increased prevalence of nonalcoholic fatty liver disease (NAFLD).

A single center, outpatient dermatology clinic studied 151 patients with psoriasis and 51 control subjects with ultrasonography to diagnose NAFLD.

Best of 2017: Cause of Death in Ankylosing Spondylitis

A French population based study of ankylosing spondylitis (AS) was report in the Journal of Rheumatology.

They analyzed the death certificates and cause of death in 2940 AS patients over 3 different decades (1969-78; 1979-99; 2000-2009).

The mortality rate of AS remained stable over time.

Ixekizumab Effective in Ankylosing Spondylitis

Eli Lilly announced today the results of the COAST-W trial showing that ixekizumab (Taltz) was effective in a Phase 3 study Ankylosing Spondylitis (AS) patients who had an inadequate response or intolerance to tumor necrosis factor (TNFi) inhibitor therapy.

NPF Dietary Recommendations for Psoriatic Disease

The National Psoriasis Foundation has released dietary recommendations for adults with psoriasis and psoriatic arthritis, based on a systematic review of the current literature, with the strongest focus on weight reduction for those who are overweight or obese.

Enthesitis in PsA: A New Focus of Treatment?

Patients with psoriatic arthritis (PsA) whose disease manifestations include enthesitis showed significantly greater responses to interleukin (IL)-23 inhibition than to blocking tumor necrosis factor (TNF), suggesting the possibility that treatment decisions in the future might be guided by specific cytokine targeting.